All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
NK cell-based cancer immunotherapy has emerged as an anticancer treatment approach and is currently being tested in clinical trials. KIR2DL5, a member of the human killer cell immunoglobulin-like receptor (KIR) family, has recently been identified as a binding partner for poliovirus receptor (PVR). However, the biology and therapeutic potential of the KIR2DL5/PVR pathway remain widely unexplored.